VICTORIA, April 16, 2019 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC
PINK: IPATF) announced today that Jennifer
Bath, President and CEO of ImmunoPrecise Antibodies, will
present at the upcoming 2019 Bloom Burton & Co. Healthcare
Investor Conference.
Date: May 1st,
2019
Time: 2:00 p.m. Eastern Time
Location: Metro Toronto Convention Centre, 255 Front St W,
Toronto, Ontario
The Bloom Burton & Co. Healthcare Investor Conference brings
together U.S., Canadian and international investors who are
interested in the latest developments in the Canadian healthcare
sector. Attendees will have an opportunity to obtain corporate
updates from the premier Canadian publicly traded and private
companies through presentations and private meetings.
Investors interested in arranging a meeting with Dr. Bath during
this conference should contact ImmunoPrecise or Bloom Burton
& Co.'s conference coordinator.
About Bloom Burton & Co.
Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm
dedicated to accelerating returns in the healthcare sector for both
investors and companies. Bloom Burton has an experienced team of
medical, scientific, pharmaceutical, legal and capital markets
professionals who perform a deep level of diligence, which combined
with our creative and entrepreneurial approach, assists our clients
in achieving the right monetization events. Bloom Burton and its
affiliates provide capital raising, M&A advisory, equity
research, business strategy and scientific consulting, advisory on
direct investing and company creation and incubation services.
Bloom Burton Securities Inc. is a member of the Investment Industry
Regulatory Organization of Canada
(IIROC) and is also a member of the Canadian Investor Protection
Fund (CIPF)
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located at the Vancouver Island Technology Park
in Victoria, British
Columbia, in collaboration with its wholly-owned subsidiary
operations at U-Protein Express B.V., in the Life Science
Incubator, Utrecht, and ModiQuest Research, Oss, both
in the Netherlands. The
Company operates globally to offer antibody services from target
analysis to pre-clinical studies.
The services offered to clients include antibody discovery
against a broad spectrum of antigens, including challenging
targets. Amongst these services, the Company offers hybridoma
production, B-cell services, and a variety of phage display
platforms. The Company also provides a broad range of supporting
services including immunologically-based assays, recombinant
protein manufacturing, humanization, optimization, stable cell line
development, and advanced solutions to challenges faced by clients
in antibody-related research and development. The antibodies
produced by ImmunoPrecise target a wide variety of therapeutic,
diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.